Autopsy report · NCT01264887

Tapentadol in Chronic Malignant Tumour Related Pain

“Administrative reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 2 months before it stopped.
• 31 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Grünenthal GmbH

Sponsor type

Industry

Conditions

Cancer; Chronic Pain; Pain

Interventions

Tapentadol Prolonged Release

Participants

31

Sites

12

Countries

Bulgaria, Hungary, Moldova, Poland, Romania, Russia, Serbia

Trials that died the same way

• An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
  “Administrative Reason” (94% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (77% match in meaning)
• Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
  “Due to administrative reason” (73% match in meaning)
• Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
  “Business Reasons” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.